Product Description
ATB-1011 is an oral candidate being developed by Autotelicbio for the treatment of hypertension and type II diabetes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05573477?term=ATB-1011&draw=2&rank=2)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Autotelicbio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension|Type 2 Diabetes
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATB-101-003 | P3 |
Unknown status |
Hypertension|Type 2 Diabetes |
2024-01-01 |
90% |
| ATB-101-003 | P3 |
Unknown status |
Hypertension|Type 2 Diabetes |
2024-01-01 |
90% |
| ATB-101-002 | P1 |
Completed |
Healthy Volunteers |
2021-07-12 |
28% |
| ATB-101-002 | P1 |
Completed |
Healthy Volunteers |
2021-07-12 |
28% |